Relay Therapeutics (RLAY) Accumulated Expenses (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Accumulated Expenses data on file, last reported at $20.9 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $20.9 million, changed 0.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.9 million (changed 0.37% YoY), and the FY2025 annual result was $13.6 million, down 35.75% from the prior year.
• Accumulated Expenses rose to $20.9 million in Q1 2026 per RLAY's latest filing, from $13.6 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $33.2 million in Q3 2024 and troughed at $13.6 million in Q4 2025.
• A 5-year average of $23.5 million and a median of $22.7 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2025: Accumulated Expenses jumped 84.3% in 2023, then sank 35.75% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $22.7 million in 2022, then tumbled by 34.41% to $14.9 million in 2023, then soared by 42.62% to $21.2 million in 2024, then slumped by 35.75% to $13.6 million in 2025, then surged by 53.26% to $20.9 million in 2026.
• Business Quant data shows RLAY's Accumulated Expenses at $20.9 million in Q1 2026, $13.6 million in Q4 2025, and $25.1 million in Q3 2025.